3C样蛋白酶 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "3C样蛋白酶" in Chinese language version.

refsWebsite

Global rank Chinese rank

24nih.gov

4^th place

5^th place

24doi.org

2^nd place

23^rd place

4web.archive.org

1^st place

3harvard.edu

18^th place

57^th place

3worldcat.org

5^th place

12^th place

2archive.org

6^th place

4^th place

1clinicaltrialsarena.com

low place

1clinicaltrials.gov

5,225^th place

4,888^th place

1pfizer.com

low place

7,863^rd place

1theregister.com

3,700^th place

4,616^th place

archive.org

Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. Journal of Virology. November 2012, 86 (21): 11754–62. PMC 3486288 . PMID 22915796. doi:10.1128/JVI.01348-12.
Ziebuhr J, Bayer S, Cowley JA, Gorbalenya AE. The 3C-like proteinase of an invertebrate nidovirus links coronavirus and potyvirus homologs. Journal of Virology. January 2003, 77 (2): 1415–26. PMC 140795 . PMID 12502857. doi:10.1128/jvi.77.2.1415-1426.2003 .

clinicaltrials.gov

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.. Clinical Trials. 24 June 2021 [3 July 2021]. （原始内容存档于2021-11-05）.

clinicaltrialsarena.com

Pfizer begins dosing in Phase II/III trial of antiviral drug for Covid-19.. Clinical Trials Arena. 2 September 2021.

doi.org

Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. June 2020, 368 (6497): 1331–1335. Bibcode:2020Sci...368.1331D. PMC 7179937 . PMID 32321856. doi:10.1126/science.abb4489 .
Ahmad, Bilal; Batool, Maria; Ain, Qurat ul; Kim, Moon Suk; Choi, Sangdun. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. 2021-08-24, 22 (17) [2022-09-16]. ISSN 1422-0067. PMC 8430524 . PMID 34502033. doi:10.3390/ijms22179124. （原始内容存档于2021-10-06）.
Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, Jonsson CB, Roush WR, McKerrow J, Craik CS. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry. July 2007, 46 (30): 8744–52. PMID 17605471. doi:10.1021/bi0621415.
Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, Lai B, Pei J, Liu Y, Chen J, Lai L. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. The Journal of Biological Chemistry. January 2004, 279 (3): 1637–42. PMC 7980035 . PMID 14561748. doi:10.1074/jbc.m310875200 .
Akaji K, Konno H, Onozuka M, Makino A, Saito H, Nosaka K. Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant. Bioorganic & Medicinal Chemistry. November 2008, 16 (21): 9400–8. PMC 7126698 . PMID 18845442. doi:10.1016/j.bmc.2008.09.057.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Maier HJ, Bickerton E, Britton P (编). Coronaviruses. Methods in Molecular Biology 1282. Springer. 2015: 1–23. ISBN 978-1-4939-2438-7. PMC 4369385 . PMID 25720466. doi:10.1007/978-1-4939-2438-7_1. See section: Virion Structure.
Ryu YB, Park SJ, Kim YM, Lee JY, Seo WD, Chang JS, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorganic & Medicinal Chemistry Letters. March 2010, 20 (6): 1873–6. ISSN 0960-894X. PMC 7127101 . PMID 20167482. doi:10.1016/j.bmcl.2010.01.152.
Chuck CP, Chow HF, Wan DC, Wong KB. Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses. PLoS One. 2011, 6 (11): e27228. PMC 3206940 . PMID 22073294. doi:10.1371/journal.pone.0027228.
Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.
Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS Journal. July 2014, 281 (18): 4085–4096. PMID 25039866. doi:10.1111/febs.12936.
Ullrich S, Nitsche C. The SARS-CoV-2 main protease as a drug target. Bioorganic & Medicinal Chemistry Letters. July 2020, 30 (17): 127377. PMID 32738988. doi:10.1016/j.bmcl.2020.127377.
Ocain TD, Rich DH. alpha-Keto amide inhibitors of aminopeptidases. Journal of Medicinal Chemistry. February 1992, 35 (3): 451–6. PMID 1738140. doi:10.1021/jm00081a005.
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. June 2003, 300 (5626): 1763–7. Bibcode:2003Sci...300.1763A. PMID 12746549. doi:10.1126/science.1085658 .
Pacifico S, Ferretti V, Albanese V, Fantinati A, Gallerani E, Nicoli F, et al. Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors. ACS Medicinal Chemistry Letters. July 2019, 10 (7): 1086–1092. PMC 6627721 . PMID 31312413. doi:10.1021/acsmedchemlett.9b00233.
Kusov Y, Tan J, Alvarez E, Enjuanes L, Hilgenfeld R. A G-quadruplex-binding macrodomain within the "SARS-unique domain" is essential for the activity of the SARS-coronavirus replication-transcription complex. Virology. October 2015, 484: 313–22. PMC 4567502 . PMID 26149721. doi:10.1016/j.virol.2015.06.016.
Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. Journal of Medicinal Chemistry. February 2020, 63 (9): 4562–4578. PMC 7098070 . PMID 32045235. doi:10.1021/acs.jmedchem.9b01828.
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. March 2020, 368 (6489): 409–412. Bibcode:2020Sci...368..409Z. PMC 7164518 . PMID 32198291. doi:10.1126/science.abb3405 .
Tian D, Liu Y, Liang C, Xin L, Xie X, Zhang D, Wan M, Li H, Fu X, Liu H, Cao W. An update review of emerging small-molecule therapeutic options for COVID-19. Biomedicine & Pharmacotherapy. May 2021, 137: 111313. PMC 7857046 . PMID 33556871. doi:10.1016/j.biopha.2021.111313.
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem. March 2020, 21 (5): 730–738. PMC 7162020 . PMID 32022370. doi:10.1002/cbic.202000047.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. March 2020, 6 (3): 315–331. PMC 7094090 . PMID 32226821. doi:10.1021/acscentsci.0c00272 .
Ramajayam R, Tan KP, Liang PH. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochemical Society Transactions. October 2011, 39 (5): 1371–5. PMID 21936817. doi:10.1042/BST0391371 .
Luttens A, Gullberg H, Abdurakhmanov E, Vo DD, Akaberi D, Talibov VO, et al. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. J Am Chem Soc. February 2022, 144 (7): 2905–2920. ISSN 0002-7863. PMC 8848513 . PMID 35142215. doi:10.1021/jacs.1c08402.
Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. Journal of Virology. November 2012, 86 (21): 11754–62. PMC 3486288 . PMID 22915796. doi:10.1128/JVI.01348-12.
Ziebuhr J, Bayer S, Cowley JA, Gorbalenya AE. The 3C-like proteinase of an invertebrate nidovirus links coronavirus and potyvirus homologs. Journal of Virology. January 2003, 77 (2): 1415–26. PMC 140795 . PMID 12502857. doi:10.1128/jvi.77.2.1415-1426.2003 .

harvard.edu

ui.adsabs.harvard.edu

Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. June 2020, 368 (6497): 1331–1335. Bibcode:2020Sci...368.1331D. PMC 7179937 . PMID 32321856. doi:10.1126/science.abb4489 .
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. June 2003, 300 (5626): 1763–7. Bibcode:2003Sci...300.1763A. PMID 12746549. doi:10.1126/science.1085658 .
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. March 2020, 368 (6489): 409–412. Bibcode:2020Sci...368..409Z. PMC 7164518 . PMID 32198291. doi:10.1126/science.abb3405 .

nih.gov

ncbi.nlm.nih.gov

Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. June 2020, 368 (6497): 1331–1335. Bibcode:2020Sci...368.1331D. PMC 7179937 . PMID 32321856. doi:10.1126/science.abb4489 .
Ahmad, Bilal; Batool, Maria; Ain, Qurat ul; Kim, Moon Suk; Choi, Sangdun. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. 2021-08-24, 22 (17) [2022-09-16]. ISSN 1422-0067. PMC 8430524 . PMID 34502033. doi:10.3390/ijms22179124. （原始内容存档于2021-10-06）.
Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, Jonsson CB, Roush WR, McKerrow J, Craik CS. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry. July 2007, 46 (30): 8744–52. PMID 17605471. doi:10.1021/bi0621415.
Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, Lai B, Pei J, Liu Y, Chen J, Lai L. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. The Journal of Biological Chemistry. January 2004, 279 (3): 1637–42. PMC 7980035 . PMID 14561748. doi:10.1074/jbc.m310875200 .
Akaji K, Konno H, Onozuka M, Makino A, Saito H, Nosaka K. Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant. Bioorganic & Medicinal Chemistry. November 2008, 16 (21): 9400–8. PMC 7126698 . PMID 18845442. doi:10.1016/j.bmc.2008.09.057.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Maier HJ, Bickerton E, Britton P (编). Coronaviruses. Methods in Molecular Biology 1282. Springer. 2015: 1–23. ISBN 978-1-4939-2438-7. PMC 4369385 . PMID 25720466. doi:10.1007/978-1-4939-2438-7_1. See section: Virion Structure.
Ryu YB, Park SJ, Kim YM, Lee JY, Seo WD, Chang JS, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorganic & Medicinal Chemistry Letters. March 2010, 20 (6): 1873–6. ISSN 0960-894X. PMC 7127101 . PMID 20167482. doi:10.1016/j.bmcl.2010.01.152.
Chuck CP, Chow HF, Wan DC, Wong KB. Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses. PLoS One. 2011, 6 (11): e27228. PMC 3206940 . PMID 22073294. doi:10.1371/journal.pone.0027228.
Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.
Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS Journal. July 2014, 281 (18): 4085–4096. PMID 25039866. doi:10.1111/febs.12936.
Ullrich S, Nitsche C. The SARS-CoV-2 main protease as a drug target. Bioorganic & Medicinal Chemistry Letters. July 2020, 30 (17): 127377. PMID 32738988. doi:10.1016/j.bmcl.2020.127377.
Ocain TD, Rich DH. alpha-Keto amide inhibitors of aminopeptidases. Journal of Medicinal Chemistry. February 1992, 35 (3): 451–6. PMID 1738140. doi:10.1021/jm00081a005.
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. June 2003, 300 (5626): 1763–7. Bibcode:2003Sci...300.1763A. PMID 12746549. doi:10.1126/science.1085658 .
Pacifico S, Ferretti V, Albanese V, Fantinati A, Gallerani E, Nicoli F, et al. Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors. ACS Medicinal Chemistry Letters. July 2019, 10 (7): 1086–1092. PMC 6627721 . PMID 31312413. doi:10.1021/acsmedchemlett.9b00233.
Kusov Y, Tan J, Alvarez E, Enjuanes L, Hilgenfeld R. A G-quadruplex-binding macrodomain within the "SARS-unique domain" is essential for the activity of the SARS-coronavirus replication-transcription complex. Virology. October 2015, 484: 313–22. PMC 4567502 . PMID 26149721. doi:10.1016/j.virol.2015.06.016.
Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. Journal of Medicinal Chemistry. February 2020, 63 (9): 4562–4578. PMC 7098070 . PMID 32045235. doi:10.1021/acs.jmedchem.9b01828.
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. March 2020, 368 (6489): 409–412. Bibcode:2020Sci...368..409Z. PMC 7164518 . PMID 32198291. doi:10.1126/science.abb3405 .
Tian D, Liu Y, Liang C, Xin L, Xie X, Zhang D, Wan M, Li H, Fu X, Liu H, Cao W. An update review of emerging small-molecule therapeutic options for COVID-19. Biomedicine & Pharmacotherapy. May 2021, 137: 111313. PMC 7857046 . PMID 33556871. doi:10.1016/j.biopha.2021.111313.
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem. March 2020, 21 (5): 730–738. PMC 7162020 . PMID 32022370. doi:10.1002/cbic.202000047.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. March 2020, 6 (3): 315–331. PMC 7094090 . PMID 32226821. doi:10.1021/acscentsci.0c00272 .
Ramajayam R, Tan KP, Liang PH. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochemical Society Transactions. October 2011, 39 (5): 1371–5. PMID 21936817. doi:10.1042/BST0391371 .
Luttens A, Gullberg H, Abdurakhmanov E, Vo DD, Akaberi D, Talibov VO, et al. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. J Am Chem Soc. February 2022, 144 (7): 2905–2920. ISSN 0002-7863. PMC 8848513 . PMID 35142215. doi:10.1021/jacs.1c08402.
Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. Journal of Virology. November 2012, 86 (21): 11754–62. PMC 3486288 . PMID 22915796. doi:10.1128/JVI.01348-12.
Ziebuhr J, Bayer S, Cowley JA, Gorbalenya AE. The 3C-like proteinase of an invertebrate nidovirus links coronavirus and potyvirus homologs. Journal of Virology. January 2003, 77 (2): 1415–26. PMC 140795 . PMID 12502857. doi:10.1128/jvi.77.2.1415-1426.2003 .

pfizer.com

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study. Pfizer Inc. 5 November 2021 [2022-09-16]. （原始内容存档于2021-11-16）.

theregister.com

AI-designed COVID-19 drug nominated for preclinical trials. www.theregister.com. [2022-05-26]. （原始内容存档于2022-12-01）（英语）.

web.archive.org

Ahmad, Bilal; Batool, Maria; Ain, Qurat ul; Kim, Moon Suk; Choi, Sangdun. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. 2021-08-24, 22 (17) [2022-09-16]. ISSN 1422-0067. PMC 8430524 . PMID 34502033. doi:10.3390/ijms22179124. （原始内容存档于2021-10-06）.
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.. Clinical Trials. 24 June 2021 [3 July 2021]. （原始内容存档于2021-11-05）.
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study. Pfizer Inc. 5 November 2021 [2022-09-16]. （原始内容存档于2021-11-16）.
AI-designed COVID-19 drug nominated for preclinical trials. www.theregister.com. [2022-05-26]. （原始内容存档于2022-12-01）（英语）.

worldcat.org

Ahmad, Bilal; Batool, Maria; Ain, Qurat ul; Kim, Moon Suk; Choi, Sangdun. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. 2021-08-24, 22 (17) [2022-09-16]. ISSN 1422-0067. PMC 8430524 . PMID 34502033. doi:10.3390/ijms22179124. （原始内容存档于2021-10-06）.
Ryu YB, Park SJ, Kim YM, Lee JY, Seo WD, Chang JS, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorganic & Medicinal Chemistry Letters. March 2010, 20 (6): 1873–6. ISSN 0960-894X. PMC 7127101 . PMID 20167482. doi:10.1016/j.bmcl.2010.01.152.
Luttens A, Gullberg H, Abdurakhmanov E, Vo DD, Akaberi D, Talibov VO, et al. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. J Am Chem Soc. February 2022, 144 (7): 2905–2920. ISSN 0002-7863. PMC 8848513 . PMID 35142215. doi:10.1021/jacs.1c08402.